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Abstract The conventional chemotherapeutic agents used
in the treatment of human malignancies are directed
nonspecifically against both malignant and nonmalignant
cells, often limiting their efficacy with having serious side
effects. Recent development of drug delivery vehicles has
opened up the possibility of targeted drug delivery systems
with the potential of achieving maximum efficacy with
minimal toxicity. The possibility of using a nanomaterial as
a combinational drug component is intuitively evident as it
would compensate the toxicity level by enhancing drug
delivery efficiency. Additionally, cell-specific cytotoxicity
(reported earlier by our group) of the nanovehicle itself may
potentiate a more effective targeted cell killing. In this
paper, we explore the possibility of using gold nano-
particles playing the dual role of an anticancer agent and a
carrier of a chemotherapeutic drug. This is demonstrated
using vincristine sulfate (VS), salt of an alkaloid often used
in the treatment of multiple myeloma (MM), and U266 as a
test MM cell line. The drug VS shows the expected G2-M-
phase arrest of cells. Notably, bare gold nanoparticle shows
arrest of the S phase cells that may be particularly important
in case of slow-growing malignancies like MM where most
of the cells remain in G1 phase of the cell cycle. The VS
conjugated gold retains the activity of both gold nano-
particle and VS leading to a synergistic rise of the apoptotic
cell population.
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1 Introduction
One important aspect in nanomedicine is focused towards
nanoparticle/drug combination. A recent study (Murphy et
al. 2008) shows that lipid-cholesterol-based nanoparticle
that is targeted towards αvβ3 integrin (an internal receptor
of a number of viruses) can work in conjugation with the
chemotherapy drug doxorubicin. The greatest advantage in
the nanoparticle based drug delivery system is that the drug
can remain active at a significantly lower dose (Barbu et al.
2009; Zhao et al. 2009).
Like integrin, cell cycle has been an important target for
new drug development in cancer therapy (de Carcer et al.
2007; Johansson and Persson 2008; Dickson and Schwartz
2009; Raucher et al. 2009). The reason for this target
identification is that the agents perturbing the cell cycle are
not disease specific and can be exploited in different classes
of malignancies. As cell cycle is a cellular network-based
event, the cycle can be targeted through multiple routes.
The antimicrotubule drug vincristine sulfate (VS), salt of a
naturally occurring alkaloid, disrupts microtubules and
mitotic spindle, resulting in cell-cycle mitotic arrest at
metaphase and apoptosis of cells (Sanchez et al. 2000). VS
is one of the most important drugs used in the treatment of
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hematological malignancies as a part of various combina-
tion chemotherapy regimens. It is highly lipophilic, and
therefore attains a several-hundred-fold higher intracellular
than extracellular concentration on administration. Howev-
er, over expression of the multidrug resistance (Huet et al.
1998; Legrand et al. 1999) transporters P-glycoprotein
(PGP) or multidrug resistance-associated protein (MRP)
can reduce the intracellular accumulation leading to drug
resistance (Calatozzolo et al. 2005; Rauch and Pluen 2007;
Ma et al. 2009). Like any chemotherapy drug, VS is also
not free from side effects, its dose limiting toxic effect
being neurotoxicity. Multiple myeloma (MM) is a differen-
tiated clonal B cell tumor usually comprising slowly
proliferating plasma cells (Zhao et al. 2010a, b). MM
constitutes around 1% of all malignant diseases and 10% of
hematological malignancies. MM is a relatively slow-
growing malignancy and is therefore difficult to treat
(Dvorak 2006). Most myeloma cells are in the G1 phase
of the cell cycle and are hence poor targets for chemother-
apy because they have ample time to repair any DNA
damage caused by many of the chemotherapeutic drugs
before they proceed to the next cell division. VS, being a
drug, causing metaphase arrest, form an important compo-
nent of various antimyeloma combination regimens.
Extending our previous example of NP-based drug
delivery systems, we can ask whether it is possible to
design a novel NP-based delivery systems that would
accentuate the activity of a drug, like VS at lower con-
centration. While lowering of concentration should lead to
minimization of the observed side effects, it is also worth
exploring whether it is possible to impart higher efficiency
in chemotherapy by arresting the cell at an earlier phase of
cell cycle. The direct effect of nanoparticle itself on cell
cycle would enhance the chemotherapeutic potential of the
drug.
Direct cancer cell killing by gold nanoparticles (GNP)
was proposed earlier by our group (Patra et al. 2007) is
different from the laser-mediated thermolysis (Lapotko et
al. 2006) using GNP. Two disadvantages of the latter
approach are the relative inaccessibility of the laser to the
target site, and thermal injury induced by the incident
laser on nontarget cell confined nanosurface. Recently,
Rotello’s group has shown that nanosurface toxicity is
indeed possible and the toxicity largely depends upon
hydrophobicity of the nanosurface (Daniel et al. 2010).
Although Rotello’s work was not aimed for any antican-
cer drug formulation and it was aimed primarily to
evaluate the toxicity of gold nanoparticle, we found the
report contextual, as in our view the ‘toxicity’ is a
contextual theme whose chemical or biochemical imprint
can have differential realization depending on the study
system. The important message from this and other works
done by Rotello and his group (Chompoosor et al. 2010;
Daniel et al. 2010; Zhu et al. 2010), is that nanosurface-
induced ROS generation and subsequent DNA damage
may give the nanosurface a special role as a drug. This
finding inspired us to attempt a nanoformulation in which
both the activity of the nanosurface and that of the drug
can be combined and the drug delivery problem is also
addressed.
2 Materials and methodology
2.1 Preparation of gold nanoparticle
The gold nanoparticles were prepared by the standard
method as described by Turkevich and Frens with some
modifications (Kimling et al. 2006). In brief, an aqueous
solution of HAuCl4 (250 μM, 25 mL) was brought to near
boiling condition upto 100°C and stirred continuously
with a magnetic stirrer. Freshly prepared trisodium citrate
solution (600 μM final concentration) was added quickly,
resulting in a change in the solution color from pale yellow
to deep red. After obtaining a stable deep red color, the
solution was then allowed to cool down to room temper-
ature with continuous stirring.
2.2 Preparation of gold nanoparticle VS conjugate
Freshly prepared aqueous solution of VS was prepared at a
stock concentration of 10 μg/ml. Aqueous solution of
HAuCl4 (250 μM, 25 mL) was heated to 60°C and stirred
continuously with magnetic stirrer. Two working solutions
of VS namely, GNP-VS1 and GNP-VS2 at final concen-
trations of 0.5 μg/ml for GNP-VS1 and 1.0 μg/ml were
prepared, respectively. They were then added to the warm
auric chloride solution with stirring for 10 min. Trisodium
citrate solution (600 μM final concentration) was added
quickly and the temperature was increased to near boiling
without allowing the solution to boil, resulting in a change
in solution color from pale yellow to bluish red. After
obtaining a stable color, the solution was then allowed to
cool down to room temperature with continuous stirring.
2.3 Characterization of the nanoparticles
The hydrodynamic diameter of the GNP and its
conjugate with VS were measured using Malvern
NanoZS80 (Malvern, UK). The laser Doppler veloc-
itimetry module of the same instrument was used to
measure the zeta potential of the nanoparticle. This
technique efficiently measures the relative velocity of
tiny particles with respect to the fluid. The zeta
potential is purely an electro kinetic property of the
electrical double layer surrounding the subject but not
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the surface of the subject itself. The conjugation was
further characterized using Plasmon resonance of the
GNP and its conjugates with VS using Thermo UV-
Visible Spectrophotometer.
2.4 Cell culture
MM cell line U266was procured fromNCCS, Pune, India and
was maintained in DMEM (Gibco-BRL, NY) supplemented
with 10% heat-inactivated fetal bovine serum (Gibco-BRL,
USA), 5×10−5 M 2-ME, 10 mM Hepes, 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin, and 1 mM
sodium pyruvate. The cell line was terated with nanoparticle
concentration (125 μM) and by VS at a concentration that
equivalent to that in GNP-VS2 conjugates. All experiments
on the treated cell line were done after 72 h.
2.5 MTT assay
In vitro cytotoxicity of GNP and its drug conjugate on MM
cells were determined by measuring 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide (MTT) dye absor-
bance of living cells. In brief, MM cells (5×106 cells per
assay) were grown in tissuce culture plates (NUNC, USA).
After treatment with GNP and GNP-VS for 48 h, 20 μL
MTT (Sigma, USA) solution (5 mg/mL in PBS) was added
to each plate and were incubated for additional 4 h at 37°C.
Following this, the MTT solution was decanted off and the
formazan crystals formed in the viable cells were dissolved
with 200 μL DMSO. The absorbance was taken at 570 nm
keeping the reference at 405 nm to measure the level of
response to GNP and GNP-VS.
2.6 DNA fragmentation assay
The DNA fragmentation was measured after extraction of
DNA from a constant number of cells (approximately 1×
106). In brief, treated and control cells were harvested,
pelleted at 1,600 rpm for 5 min, washed twice with PBS,
and resuspended in 60 μL of lysis buffer (10 mM EDTA,
50 mM Tris–HCl, pH 8.0, 0.5% SDS, 0.5 mg/mL
proteinase-K). The solution was mixed and incubated
overnight at 37°C followed by addition of 3 μL of
10 mg/mL DNAse-free RNase-A. After digestion of
RNA, gel electrophoresis was performed on a 1.5% agarose
containing ethidium bromide. The gels were documented
by imaging with UV transillumination.
3 Cell-cycle analysis
Cell-cycle assay for the amount of DNA distribution was
determined by staining DNA with PI (propidium iodide)
(Sigma). In brief, after treatment for 24 h, nearly 1×106
cells were washed in PBS and fixed in 70% ethanol and
kept for overnight at −20°C. The fixed cells were washed
twice with PBS and then subjected to PI (10 μg) and RNase
treatment at 37°C for 1 h. Cell-cycle analysis by flow
cytometry was done to determine the percentage of cells in
different phases of cell cycle using a FACS Calibur (BD
Biosciences, USA) instrument.
4 Annexin V staining
The annexin V staining was performed for the determi-
nation and quantitation of the percentage of cells
undergoing apoptosis for GNP and its drug conjugate
(GNP-VS). In brief, after treatment, the cells were
washed twice with cold PBS and resuspended in binding
buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl,
2.5 mM CaCl2) at a concentration of 1×10
6 cells/mL. A
100 μL of the suspended cells in binding buffer was
transferred to a 5-mL culture tube, and 5 μL of Annexin
V-FITC and 10 μL of PI were added. The solution was
mixed properly and incubated for 15 min at room
temperature in the dark. At the end of incubation,
400 μL of binding buffer was added, and the cells were
analyzed immediately by flow cytometry. Flow cytometric
analysis was performed with the FACSCalibur using the
CellQuest software (BD, USA).
5 Results
5.1 GNP and its conjugates with VS
5.1.1 UV-VIS spectroscopy
Figure 1 describes the normalized UV-VIS absorption
spectra of GNP (blue line) and its conjugates, GNP-VS1
(green line) and GNP-VS2 (red line). An intense and sharp
surface plasmon absorption peak at 517 nm attributed to
GNP collective electron oscillations or localized surface
plasmon resonance is presented and is a feature of gold
nanoclusters. It is clear that the plasmon absorption peak of
GNP shifts to 519 nm (GNP-VS1) and 523(GNP-VS2) nm
after the conjugation with VS. The resonance wavelength
and bandwidth of nanoparticles are dependent on the
particle size and shape, the refractive index of the
surrounding medium and the temperature.
5.1.2 Dynamic light scattering
Dynamic Light Scattering study shows (Fig. 2a) statisti-
cal size distribution of GNP and its drug conjugates GNP-
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VS1 and GNP-VS2. The hydrodynamic sizes of the
nonmaterial are around 25 nm. The comparative distribu-
tion (see Fig. S2 in the Electronic supplementary material)
shows the broadening of the distribution pattern that can
be described due to the formation of the GNP-VS (green
and blue) than that of the GNP (red). From the
measurement of the zeta potential (ς) data, it has been
shown (Fig. 2b) there is a gradual shift of the ς value when
the GNP has been conjugated with VS. This evidence is
expected because the drug molecules will replace the
citrate molecules during conjugation as a result of which
there is a gradual drop and shift of ς value. In this case
the steric factor of the drug molecule will contribute to
stabilize the particle in colloid.
5.1.3 Fourier transform infrared spectroscopy
The Fourier transform infrared (FTIR) spectra of VS,
GNP (see Electronic supplementary material) and GNP-
VS conjugates with VS are shown in Fig. 3. The peaks are
characterized and marked. Direct evidences of conjuga-
tion was observed from peaks at 1,910–1,970 cm−1 for C–
H alkyl stretching, 2,549 cm−1 due to S–H deformation
and 701 cm−1 for thiol stretching. C=O stretch at
1923 cm−1 and 1,666 cm−1 along with the N–C stretch
at 1,621 cm−1, 1,615 cm−1 confirms the bond level
interaction of VS with GNP. Several other peaks appeared
at 758 and 1,620 cm−1, which are associated with the N–
H deformation and stretching vibration, respectively.
These results suggest the conjugation of VS with GNP
via bond between gold and sulfur, gold and nitrogen in
the stable drug-gold conjugate. For further analysis and





bromide) has been employed to study the survival rate of
the cells in Fig. 4a. Notably, both VS- and GNP-treated
cells showed lower percentage of survival. Further reduc-
tion in survival was observed in GNP-VS1 and GNP-VS2
cells with lesser survival with GNP_VS2.
In contrast to the cancer cells, PBMC (peripheral blood
mononuclear cells) did not show any alteration in percent-
age survival pattern when challenged with GNP, VS, GNP-
VS conjugates (Fig. 4b).
5.2.2 PI uptake
Cell damage was also assayed with propidium iodide (PI)
uptake studies (Fig. 5). Plasma membrane integrity was
altered in presence of VS, GNP, and GNP-VS conjugates.
In each case, there was higher density of points (represent-
ing individual cell) in the upper half of the dot plot (Fig. 5a)
implying higher PI entry after treatment with VS, GNP, and
GNP-VS conjugates, the effect being dramatically higher
for GNP-VS2.
Figure 4 describes survival rate on the basis of the
metabolic activity of the cells. The reducing nature in GNP-
VS conjugates seems to retard the metabolic rate of the
population. This is illustrated by the relative bar heights in
Fig. 4. Importantly, there is also an associated loss of
plasma membrane integrity upon such conjugation causing
enhancement of PI uptake. Reverse is the case for intact
plasma membranes, where PI’s are excluded even in case of
cell death (see Fig. 5).
Fig. 1 The normalized UV-VIS
absorbance spectra of GNP and
GNP-VS. The λmax is 517, 519,
and 523 nm for GNP, GNP-
VS1, and GNP-VS2,
respectively
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5.2.3 Annexin-V
We now need to explore whether the observed cell death is
mediated by apoptosis or necrosis, the two different mech-
anisms by which cells die (Lieberthal et al. 1996; Kostrzewa
2000; Anselmi et al. 2002; Catelas et al. 2005; Vairetti et al.
2005). The dynamics in these two processes differ greatly.
The plasma membrane damage occurs as a primary event
during necrosis whereas a delayed but massive programmed
phenomenon occurs during apoptosis. In Fig. 5, we have
shown only the population of the dead cells, but the
mechanism of the event is unexplored. In apoptotic cells,
the membrane phospholipid phosphatidylserine is flipped
from the inner to the outer leaflet of the plasma membrane,
hence exposed to the extracellular environment (Kekre et
al. 2005). Annexin V, Ca2+-dependent phospholipid-binding
protein, conjugated with FITC has been used with flow
cytometry to measure this event. Annexin V-FITC assay as
shown in Fig. 6 has identified apoptosis as the early stage
event. Interestingly, this followed the DNA fragmentation in
the nucleus which is a late apoptotic event (data not shown).
The population density as shown in Fig. 6a gradually shifted
to higher fluorescence while conjugated with VS. The
qualitative shifting of the population has been shown in
Fig. 6b and the respective quantitation has been shown in
Fig. 6c. Now Fig. 6 describes that the cells are undergoing
apoptosis in presence of either GNP or VS. For GNP con-
jugated with VS there is a cumulative effect.
Fig. 2 a Intensity statistics of
hydrodynamic diameter of the
nanoparticles is described. b
Zeta potential of
nanoparticles-GNP (red line) is
around −40 mV and gradually
shifted to −20 mV during
conjugation with VS
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Dual Staining of annexin V–FITC with propidium iodide
(PI) was then used (Fig. 7) for identification of early
apoptotic cells (PI negative, Annexin V-FITC positive)
from dead cells (PI positive, annexin V–FITC positive). In
Fig. 7, the different kinetics of Propidium iodide incorpo-
ration by necrotic and apoptotic cells (annexin V positive)
after treatment with different GNP and its VS conjugates
have been represented along with the control. Figure 7a
represents the basis for the flow cytometric identification
(dot plot) of different cellular subsets by defining appro-
priate quadrant. The dual positivity (both annexin V
positive and Propidium Iodide positive) of the GNP-VS-
treated cells strongly implies that the cells are undergoing
apoptosis.
5.2.4 Cell cycle
As VS-mediated chemotherapy is primarily targeted
towards the cell cycle, cell-cycle analysis was performed
with GNP, VS, and GNP-VS. The relative cellular DNA
content was identified by the distribution of the cells
during the various phases of the cell cycle. Four distinct
phases were recognizing in a proliferating cell popula-
tion as represented in Fig. 8: G0/G1, S (DNA synthesis
phase), and G2/M-phase (mitosis), indicated as M2, M3,
and M4, respectively, in the histogram. In G2 and M-
phase there is a single population of cells showing
identical DNA content (M4). VS was found to affect
cells in interphase, producing a transient G2 block with
Fig. 4 a The survivality of U266 cell line with corresponding control
and treatment. b The corresponding response to PBMC
Fig. 3 The Fourier transform infrared spectrum of VS (pink), GNP-VS1 (green) and GNP-VS2 (red), respectively. The alteration in the peak
intensity and pattern was marked with corresponding wavenumbers (cm−1)
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all drug conjugates (GNP-VS1 and GNP-VS2). Meta-
phase index in case of VS was increased as expected,
vincristine being a well-known G2/M blocker.
The cell-cycle pattern was affected by GNP, and in a
way that was significantly different from cell-cycle shift
induced by VS. In case of GNP, there seems to be an
arrest at the S phase of the cell cycle. As shown in
Fig. 8a, the G2/M-phase cells are increasing in case of
treatment with VS. From the histogram described in
Fig. 8a, the GNP-VS conjugates show the cumulative
Fig. 6 a The dot plot of the annexin V staining. b The histogram pattern annexin V staining. c The quantitative estimation of annexin V staining
Fig. 5 a The dot plot of PI uptake of the myeloma cell line U266. b The histogram pattern of the population with PI uptake. c The quantitative
estimation of the PI uptake
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response of both the cell-cycle effectors namely GNP and
VS. Figure 8b illustrates the different response of the cell
cycle using a contour plot, in which the VS-, GNP-, and
the GNP-VS-induced population shift are clearly classi-
fied. The analysis further reveals that there is an increase
in less-than-2n population. This provides evidence for an
onset of DNA fragmentation at the late apoptotic phase
of cells in presence of VS, GNP, or GNP-VS.
G2/M population is increased in response to VS as
expected, implying a mitotic block, a well-known signature
of VS. On the other hand, in case of GNP-VS an additional
feature, namely, a decrease of the G0/G1 cell population is
thus observed.
Conjugation of drug (here VS) with gold nanoparticle is
done successfully by a novel synthesis method. After
conjugation, the newly postulated drug (GNP-VS) has
achieved unique cell killing properties. The results indicate
that Gold conjugated vincristine nanoparticle kills cancer cell
line by blocking at synthesis phase (S phase) of cell cycle.
The use of GNP as a drug delivery agent is already
established. This is, to our knowledge, the first report
describing cell-cycle perturbation by gold nanoparticles.
The cumulative effect of GNP and VS on cell cycle makes
the combination prospective in chemotherapy of slow-
growing cells like MM. The dual role of GNP as a drug
carrier and a drug affecting the cell cycle is also an
important outcome of the work.
6 Discussion
Killing cells remains the backbone of chemotherapeutic
approaches to human malignancies. Most of the conven-
tional chemotherapeutic agents are directed nonspecifically
against both malignant and nonmalignant cells, limiting the
efficacy of the drugs vis-à-vis enhancing their toxicity. As
such, intense research is going on to develop newer agents
targeted specifically against malignant cells. VS is the salt
of a naturally occurring nitrogenous base derived from the
pink periwinkle plant, Catharanthus roseus, vincristine is
an asymmetric dimeric compound that binds to the protein
tubulin and, at low concentrations, inhibits microtubule
dynamics. At higher concentrations, it disrupts micro-
tubules and mitotic spindle, resulting in cell-cycle mitotic
arrest at metaphase. A smart formulation of the drug (VS)
that further affects the cell cycle without invoking any
appreciable toxicity is likely to be welcome in MM
treatment. As VS is primarily eliminated through the liver
into the bile and feces, patients with obstructive liver
disease are more susceptible to its toxic effects, requiring a
dose reduction depending upon the serum bilirubin con-
centration. Vincristine uniquely spares the kidney and the
bone marrow. As a result, they are continued to be used
extensively in the treatment of various hematological
malignancies, as a component of combination chemother-
apy regimens that also includes more myelotoxic agents. As
Fig. 7 a The dot plot of dual (annexin V-FITC and PI) staining. b The quantitative estimation of dual staining
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Fig. 8 a Histogram of DNA content of the population. b The contour plot of the DNA content. c–d The quantitative estimation of cell cycle
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nanoparticles are shown to reduce the required VS dose
(see Figs. 4 and 5), the GNP based drug formulation is
expected to reduce the toxic side effects associated with
conventional chemotherapy. The arrest at S phase cells by
GNP may be of potential important to MM therapy. The
renal sparing action of VS has helped design chemotherapy
regimens, like vincristine-adriamycin-dexamethasone
(VAD) that may be used to treat patients of MM with renal
insufficiency. The VAD regimen (Barlogie et al. 1984) has
been shown to produce rapid rate of response, but the
survival duration achieved is no longer than the most
commonly used standard treatment combination of mel-
phalan and prednisolone (Alexanian et al. 1990). It has
been shown that the activity of the VAD regimen is almost
entirely due to high-dose dexamethasone (Alexanian et al.
1992). Probably only mature plasma cells are killed by
dexamethasone, whereas the immature, clonogenic myelo-
ma compartment can be rescued from dexamethasone-
induced apoptosis by IL-6, an important cytokine secreted
by myeloma cells.
The future use of GNP conjugation with VS and
perhaps, the other MM drugs, may open up possibilities
for newer chemotherapeutic regime in which this dual role
of the nanoparticle is exploited, lower drug concentration
may be used and higher drug potential may be achieved at a
much reduced level of toxicity.
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